User profiles for Lluís Puig

Lluis Puig

Head, Department of Dermatology, Hospital de la Santa Creu i Sant Pau
Verified email at santpau.cat
Cited by 28323

[HTML][HTML] La prevalencia de diez enfermedades inflamatorias inmunomediadas (IMID) en España

L Puig, JG Ruiz de Morales, E Dauden… - … Española de Salud …, 2020 - SciELO Public Health
Fundamentos: Las enfermedades inflamatorias inmunomediadas (IMID) son enfermedades
crónicas y altamente discapacitantes que comparten secuencias inflamatorias y …

[HTML][HTML] Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

JMGR de Morales, L Puig, E Daudén, JD Cañete… - Autoimmunity …, 2020 - Elsevier
Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive
research because of its crucial role in the pathogenesis of different diseases across many …

[PDF][PDF] Pointed groups and construction of modules

L Puig - Journal of Algebra, 1988 - core.ac.uk
Puig’s pointed groups correspond one-to-one to the [isomorphism classes of] indecomposable
AH-direct summands of A where H runs over all the subgroups of G. It follows that all his …

[HTML][HTML] Secukinumab in plaque psoriasis—results of two phase 3 trials

…, K Reich, CEM Griffiths, K Papp, L Puig… - … England Journal of …, 2014 - Mass Medical Soc
Background Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We
evaluated secukinumab, a fully human anti–interleukin-17A monoclonal antibody, in …

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial

IB McInnes, A Kavanaugh, AB Gottlieb, L Puig… - The Lancet, 2013 - thelancet.com
Background Many patients with psoriasis develop psoriatic arthritis, a chronic inflammatory
disease that afflicts peripheral synovial, axial, and entheseal structures. The fully human …

Inflammatory, immune-mediated adverse reactions related to soft tissue dermal fillers

…, MT Fernández-Figueras, L Puig - Seminars in arthritis and …, 2013 - Elsevier
Background An increasing number of persons seek medical solutions for esthetic indications
and for diverse pathological conditions, such as malformations, trauma, or cancer. Despite …

[HTML][HTML] Cardiometabolic comorbidities in psoriasis and psoriatic arthritis

L Puig - International journal of molecular sciences, 2017 - mdpi.com
There is solid epidemiologic evidence linking psoriasis and psoriatic arthritis (PsA) to
cardiovascular risk factors and an increased risk of developing cardiovascular disease. Chronic …

Psoriasis y su relación con el síndrome metabólico

Á Londoño, C González, L Castro, L Puig - Revista Colombiana de …, 2013 - Elsevier
Lluís Puig ha recibido honorarios en concepto de asesorías y/o conferencias de Abbvie,
Boehringer, Janssen, Merck-Serono, MSD, Novartis y Pfizer. Ha participado en ensayos …

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled …

…, A Blauvelt, Y Poulin, KA Papp, H Sofen, L Puig… - The Lancet, 2018 - thelancet.com
Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation. We …

Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey

…, A Kavanaugh, RG Langley, CF Paul, L Puig… - Journal of the American …, 2014 - Elsevier
Background Available psoriasis surveys offer valuable information about psoriasis and psoriatic
arthritis (PsA), but are limited by methodology or enrollment requirements. Objective To …